TMO — THERMO FISHER SCIENTIFIC INC.

NYSE · Unknown · Unknown · CIK 97745 ·
Last close
$603.01
Market Cap
$222.96B
52W High
$606.21
52W Low
$434.83
ADV30
2,100,273
Next earnings
2026-10-21
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026
Mar 2026 11,005,000,000 4,430,000,000 1,913,000,000 1,651,000,000 113,281,000,000 3,254,000,000 61,220,000,000
Dec 2025 12,215,000,000 5,011,000,000 2,303,000,000 1,964,000,000 110,343,000,000 9,852,000,000 56,807,000,000
Sep 2025 11,122,000,000 4,583,000,000 2,075,000,000 1,616,000,000 103,020,000,000 1,982,000,000 51,866,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$8,290,000,000
Investing CF
$-12,483,000,000
Financing CF
$2,995,000,000
CapEx
$-1,539,000,000
Dividends Paid
$-649,000,000
Buybacks
$-4,000,000,000
EPS Diluted TTM
$18.59
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$60,632,000,000
Inventory
$5,496,000,000
Receivables
$10,888,000,000
ST Investments
$2,000,000
EBIT TTM
$8,892,000,000
Pretax Income TTM
$7,422,000,000
Interest Exp TTM
$1,470,000,000
Analysts
26

Yahoo Snapshot (yfinance, live)

Total Revenue
$46,336,000,000
EBITDA
$11,738,999,808
Free Cash Flow
$6,237,250,048
Enterprise Value
$262,310,100,992
Total Cash
$4,064,000,000
Total Debt
$42,548,998,144
Shares Out
369,747,286
Trailing EPS
$18.51
Book Value
$142.47
ROE
13.5%
ROA
5.1%
Div Yield
0.31%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 44,557,000,000 8,110,000,000 6,704,000,000 110,343,000,000 56,807,000,000 7,818,000,000
Dec 2024 42,879,000,000 7,717,000,000 6,335,000,000 97,321,000,000 47,649,000,000 8,667,000,000
Dec 2023 42,857,000,000 7,318,000,000 5,995,000,000 98,726,000,000 51,884,000,000 8,406,000,000
Dec 2022 44,915,000,000 8,507,000,000 6,950,000,000 97,154,000,000 53,006,000,000 9,154,000,000

TTM Snapshot

Revenues TTM
$41,179,000,000
NetIncome TTM
$6,742,000,000
OpCashFlow TTM
$0
Assets (Latest)
$97,321,000,000
Forward EPS
$27.51

Max Pain — expiry 2026-08-21

max pain strike: $550.00 · spot: $595.93 · call oi: 5,798 · put oi: 3,392

Peers — same industry

TickerNameMarket CapLastDaily %
IBM INTERNATIONAL BUSINESS MACHINES CORP $222.32B $235.98
KLAC KLA CORP $272.09B $208.25
KXIAY Kioxia Holdings Corporation/ADR $178.29B $32.58
QQQ INVESCO QQQ TRUST, SERIES 1 $284.49B $723.70
SMEGF Siemens Energy AG/ADR $159.40B $187.34

News headlines (Yahoo Finance, 1h cache)

Thermo Fisher closes $1.1B sale of microbiology unit to PE firm
2026-08-13 11:19 · Yahoo
Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)
2026-08-12 23:16 · Yahoo
LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance
2026-08-12 22:09 · Yahoo
Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist
2026-08-12 12:10 · Yahoo
Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
2026-08-12 12:00 · Yahoo
Following Hamamatsu's Rebranding of NKT Photonics to Drive Laser Innovation, New Biophotonics Market Overview Maps Strategic Growth Through 2030
2026-08-12 11:20 · Yahoo
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
2026-08-12 01:04 · Yahoo
Can A New Vitiligo Registry Move The Needle For Thermo Fisher (TMO)?
2026-08-11 21:20 · Yahoo
Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson’s Precision Medicine
2026-08-11 12:30 · Yahoo
Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Sci
2026-08-11 08:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.